持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2024/07/12 | 日証協 | 202,237株 | -7.96% | 208,902株 | -33.1% | 206,436株 | -0.89% | 13,800株 | -65.09% |
2024/07/05 | 日証協 | 219,731株 | +1.78% | 312,242株 | +15.07% | 208,283株 | +2.86% | 39,526株 | +68.86% |
2024/06/28 | 日証協 | 215,882株 | +3.25% | 271,346株 | -9.51% | 202,490株 | +0.8% | 23,407株 | +11.79% |
2024/06/21 | 日証協 | 209,080株 | -3.66% | 299,873株 | +11.66% | 200,883株 | -4.85% | 20,939株 | -2.18% |
2024/06/14 | 日証協 | 217,033株 | +3.5% | 268,561株 | -26.69% | 211,112株 | +1.07% | 21,405株 | -42.02% |
2024/06/07 | 日証協 | 209,702株 | -8.43% | 366,318株 | +21.96% | 208,883株 | -8.52% | 36,916株 | -10.18% |
2024/05/31 | 日証協 | 229,017株 | +3.2% | 300,351株 | -42.17% | 228,347株 | -0.18% | 41,099株 | -3.06% |
2024/05/24 | 日証協 | 221,914株 | +20.06% | 519,350株 | +109.38% | 228,766株 | +9.48% | 42,397株 | +36.7% |
2024/05/17 | 日証協 | 184,832株 | +1.32% | 248,044株 | +77.9% | 208,958株 | -0.76% | 31,015株 | +324.86% |
2024/05/10 | 日証協 | 182,427株 | -7.96% | 139,429株 | +104.8% | 210,558株 | -6.41% | 7,300株 | -3.44% |
2024/05/02 | 日証協 | 198,211株 | -14.68% | 68,079株 | -67.37% | 224,990株 | -11.33% | 7,560株 | -16% |
2024/04/26 | 日証協 | 232,322株 | -2.56% | 208,624株 | +30.18% | 253,733株 | -1.28% | 9,000株 | -21.1% |
2024/04/19 | 日証協 | 238,417株 | -0.21% | 160,264株 | -72.63% | 257,032株 | +1.48% | 11,407株 | -87.29% |
2024/04/12 | 日証協 | 238,907株 | +51.93% | 585,634株 | +127.12% | 253,276株 | +29.51% | 89,761株 | -21.78% |
2024/04/05 | 日証協 | 157,250株 | +129.81% | 257,848株 | +131.61% | 195,565株 | +54.64% | 114,755株 | +14.55% |
2024/03/29 | 日証協 | 68,427株 | +6.09% | 111,330株 | +7.99% | 126,463株 | +34.97% | 100,177株 | +470.84% |
2024/03/22 | 日証協 | 64,496株 | -56.23% | 103,097株 | -47.85% | 93,698株 | -44.75% | 17,549株 | +0.29% |
2024/03/15 | 日証協 | 147,339株 | +7.52% | 197,712株 | -31.29% | 169,598株 | -5.3% | 17,499株 | -50.57% |
2024/03/08 | 日証協 | 137,029株 | -21.11% | 287,752株 | -4.74% | 179,098株 | -16.68% | 35,400株 | -66.2% |
※株式分割は考慮していませんのでご注意ください。
Page Top